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Hepatic metabolic derangements are key compo-
nents in the development of fatty liver, insulin resis-
tance, andatherosclerosis.SIRT1,aNAD+-dependent
protein deacetylase, is an important regulator of
energy homeostasis in response to nutrient avail-
ability. Here we demonstrate that hepatic SIRT1 regu-
lates lipid homeostasis bypositively regulatingperox-
isome proliferators-activated receptor a (PPARa), a
nuclear receptor thatmediates the adaptive response
to fasting and starvation. Hepatocyte-specific dele-
tion of SIRT1 impairs PPARa signaling and decreases
fatty acid b-oxidation, whereas overexpression of
SIRT1 induces the expression of PPARa targets.
SIRT1 interactswithPPARaand is required toactivate
PPARa coactivator PGC-1a. When challenged with
a high-fat diet, liver-specific SIRT1 knockout mice
develop hepatic steatosis, hepatic inflammation, and
endoplasmic reticulum stress. Taken together, our
data indicate that SIRT1 plays a vital role in the
regulation of hepatic lipid homeostasis and that phar-
macological activation of SIRT1 may be important
for the prevention of obesity-associated metabolic
diseases.
INTRODUCTION
Metabolic syndrome—a collection of abnormalities including
obesity, type 2 diabetes, dyslipidemia, fatty liver, and a proin-
flammatory and prothrombotic state (Eckel et al., 2005; Grundy
et al., 2004; Zimmet et al., 2001)—affects more than 27% of
adults in the United States (Ford et al., 2004; Hedley et al.,
2004) and has become a major health concern worldwide.
Central to the pandemic of this disease cluster is the dramatic
increase in the incidence of obesity in most parts of the world.
Obesity-induced ectopic accumulation of fat activates cellular
stress signaling and inflammatory pathways (Hirosumi et al.,
2002; Ozcan et al., 2004; Yuan et al., 2001), contributing to
enhanced muscle insulin resistance, pancreatic b cell failure,
nonalcoholic steatohepatitis (NASH), and eventually to organdamage. Therefore, efforts to achieve a better understanding
of the molecular mechanisms controlling lipid and energy
metabolism are crucial to the development of new therapeutic
strategies.
The liver is the central metabolic organ that regulates several
key aspects of lipid metabolism including fatty acid b-oxidation,
lipogenesis, and lipoprotein uptake and secretion, in response to
nutritional and hormonal signals (van den Berghe, 1991). It is
essential for the maintenance of systemic energy homeostasis
in the body. For example, during the fed state, dietary glucose
stimulates insulin secretion from the pancreas, which travels
directly to the liver via the portal vein, thus increasing hepatic
lipogenesis and lipoprotein secretion. Conversely, upon fasting,
hepatic fatty acid oxidation is enhanced in response to the
release of pancreatic glucagon and adrenal cortisol. Dysregula-
tion of lipid metabolic pathways results in the development of
hepatic steatosis and contributes to the development of chronic
hepatic inflammation, insulin resistance, and liver damage
(Browning and Horton, 2004; Samuel et al., 2004; Sanyal, 2005).
The capacity of the liver to regulate metabolism is governed by
a highly dynamic transcriptional regulatory network. The key
regulatory factors include members of the adopted orphan
nuclear receptors, particularly peroxisome proliferators-acti-
vated receptor a (PPARa), farnesoid X receptor (FXR), and liver
X receptor (LXR) (Chawla et al., 2001). This class of nuclear
receptors forms heterodimers with the retinoid X receptor
(RXR) and functions as lipid sensors through the direct binding
of a variety of lipids and their derivatives to their ligand-binding
domain. Upon lipid binding, each of these receptors activates
the transcription of a family of genes involved in lipid homeo-
stasis, thereby modulating hepatic and systemic energy
metabolism in response to nutrient availability (Shulman and
Mangelsdorf, 2005). Recent studies have demonstrated that
SIRT1, a nuclear NAD+-dependent protein deacetylase (Imai
et al., 2000; Landry et al., 2000; Smith et al., 2000), plays an
important role in the regulation of transcriptional networks in
various critical metabolic processes. SIRT1 belongs to the class
III family of histione deacetylases (HDACs), also known as sir-
tuins (Blander and Guarente, 2004). Members of the sirtuin family
are longevity determinants in yeast, C. elegans, and Drosophila
and are essential for life-span extension provided by calorie
restriction (Blander and Guarente, 2004). Because sirtuin activity
is dependent on NAD+, an indicator of cellular nutrient status,
they are believed to provide a functional link betweenCell Metabolism 9, 327–338, April 8, 2009 ª2009 Elsevier Inc. 327
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Hepatic SIRT1 Regulates Fatty Acid OxidationFigure 1. Hepatic Deletion of SIRT1 Alters PPARa Signaling
(A) Microarray analysis of PPARa signaling pathway from control and SIRT1 LKO mice (n = 6, 2 per lane). The log ratios of SIRT1 LKO/control were presented by
heat map.
(B) Venn-diagram representation of the subset of PPARa-regulated hepatic fatty acid metabolism genes that were significantly decreased in the liver of SIRT1
LKO mice.
(C and D) Quantitative real-time PCR (qPCR) analysis of PPARa target genes involved in fatty acid oxidation in the liver of control (black bars) and SIRT1 LKO mice
(white bars) on the chow diet, sacrificed at 4 p.m. (C) or after a 16 hr fast (D). (Data represent mean ± SEM, n = 6, *p < 0.05.)metabolism, chromatin structure, and ultimately aging (Bishop
and Guarente, 2007). The mammalian genome consists of seven
sirtuins, collectively known as SIRT1–SIRT7 (Frye, 2000). SIRT1
has been shown to deacetylate many nonhistone proteins,
including p53 (Luo et al., 2001; Vaziri et al., 2001), NFkB (Yeung
et al., 2004), FOXO transcriptional factors (Brunet et al., 2004;
Motta et al., 2004), PGC-1a (Rodgers et al., 2005), LXR (Li
et al., 2007), CLOCK and PER2 (Grimaldi et al., 2008; Nakahata
et al., 2008), and TORC2 (Liu et al., 2008). Through its deacety-
lase activity, SIRT1 is able to either repress or activate the tran-
scriptional activities of these targets, thereby regulating diverse
metabolic and stress pathways (Guarente, 2006). In this report,
we show that hepatic SIRT1 is an important regulator of lipid
homeostasis, in particular fatty acid oxidation. Loss of SIRT1
in hepatocytes impairs the activity of PPARa, resulting in
decreased fatty acid oxidation, leading to the development of
hepatic steatosis and inflammation on a high-fat diet.328 Cell Metabolism 9, 327–338, April 8, 2009 ª2009 Elsevier Inc.RESULTS
Hepatic Deletion of SIRT1 Alters PPARa Signaling
SIRT1 is an important regulator of nutrient homeostasis in several
tissues involved in metabolism (Guarente, 2006). To examine the
function of SIRT1 in the liver, we generated liver-specific SIRT1
knockout mice on the C57BL/6 background (SIRT1 LKO, see
Experimental Procedures and Figure S1). Although SIRT1 LKO
mice were phenotypically normal under a chow diet, microarray
analysis and Ingenuity Pathway Analysis (IPA) of liver mRNA
identified the PPARa signaling pathway as one of the main path-
ways affected by hepatic SIRT1 deficiency (Figure 1A, p = 1.993
106). Previous studies have identified 48 PPARa response
genes that are involved in hepatic fatty acid oxidation (FAO);
ketone body synthesis; and fatty acid binding, transport, and
activation (Rakhshandehroo et al., 2007). Subsequent analysis
revealed that 25 of these genes were significantly decreased in
Cell Metabolism
Hepatic SIRT1 Regulates Fatty Acid OxidationFigure 2. Loss of SIRT1 Reduces the Induction of PPARa Targets and Fatty Acid Oxidation in Primary Hepatocytes
(A) SIRT1 deficiency in primary hepatocytes reduces the induction of fatty acid oxidation gene expression by PPARa agonist WY14643. Primary hepatocytes from
control (black bars) or SIRT1 LKO mice (white bars) were treated as described in the Experimental Procedures, and mRNA were analyzed by qPCR. (Data repre-
sent mean ± SEM, n = 3, *p < 0.05.)
(B) SIRT1 deficiency in primary hepatocytes reduces the rate of fatty acid oxidation. The oxidation rate of 3H-palmitic acid in primary hepatocytes from control
(black bars), and SIRT1 LKO (white bars) mice were measured as described in the Experimental Procedures. (Data represent mean ± SEM, n = 3, *p < 0.05.)
(C) SIRT1-deficient primary hepatocytes show reduced induction of other PPARa targets by WY14643. (Data represent mean ± SEM, n = 3, *p < 0.05.)
(D) Overexpression of SIRT1 in primary hepatocytes induces the expression of PPARa targets. Primary hepatocytes from control and SIRT1 LKO mice were
infected with lentiviruses expressing GFP (white bars) or SIRT1 (black bars) and mRNA were analyzed by qPCR. (Data represent mean ± SEM, *p < 0.05.)SIRT1 LKO mice (Figure 1B and Table S1), indicating that loss of
hepatic SIRT1 impairs PPARa-mediated fatty acid metabolism.
Quantitative real-time PCR (qPCR) confirmed decreased expres-
sion of several PPARa targets, including medium chain acyl-CoA
dehydrogenase (MCAD), liver bifunctional enzyme (Ehhadh),
palmitoyl acyl-CoA carboxylase (AOX), fatty acid transporter
(CD36), and microsomal cytochrome P450 enzymes involved in
the u-oxidation of fatty acids (Cyp4A10 and Cyp4A14), in
SIRT1 LKO mice compared to Lox controls (control, Figure 1C).
In contrast, the mRNA level ofSPOT14, a gene known to be nega-
tively regulated by PPARa (Ren et al., 1996), was significantly
higher in the SIRT1 LKO mice.
PPARa is a lipid-sensing member of the nuclear receptor
superfamily that regulates systemic fatty acid metabolism. Under
normal physiological conditions in mice, PPARa levels in the liver
peak in the late afternoon and decrease immediately after
food intake (Yang et al., 2006), (http://www.nursa.org/10.1621/
datasets.02002). Activation of PPARa by fatty acids and metabo-
lites leads to transcriptional activation of various target genes
involved in fatty acid oxidation, which are required for the normal
adaptive response to starvation. Consequently, mice lacking
PPARa accumulate excessive triglyceride in their liver and
become hypoketonemic during fasting (Hashimoto et al., 2000;
Kersten et al., 1999). To further confirm the involvement of
SIRT1 in PPARa-mediated pathways, we examined expression
levels of PPARa targets in SIRT1 LKO mice and Lox controls after
overnight fasting. Consistent with our previous findings (Figures
1A–1C), SIRT1 LKO mice displayed reduced expression ofseveral PPARa target genes after overnight fasting (Figure 1D).
Interestingly, the expression of PPARg coactivator 1a (PGC-1a),
a transcription cofactor known to activate PPARa (Vega et al.,
2000), was also significantly lower in SIRT1 LKO mice. Taken
together, these results suggest that SIRT1 may play a role in regu-
lating PPARa signaling during physiological conditions of fasting.
SIRT1 Regulates Ligand-Dependent PPARa Activation
To elucidate the regulatory role of SIRT1 in PPARa signaling in
liver, we treated primary hepatocytes from Lox control or SIRT1
LKO mice with a PPARa agonist WY14643. As shown in Fig-
ure 2A, WY treatment induced the expression of several genes
involved in fatty acid oxidation in control hepatocytes. However,
the induction of these genes was significantly lower in the
SIRT1-deficient (LKO) hepatocytes (Figure 2A). Consistent with
a reduction in fatty acid oxidation gene expression, b-oxidation
of 3H-palmitate in SIRT1-deficient hepatocytes was significantly
lower compared to that in control hepatocytes (Figure 2B).
PPARa is also known to induce the expression of additional
targets involved in fatty acid metabolism such as acyl-CoA
thioesterases (Acots) (Hunt et al., 1999). As shown in Figure 2C,
mRNA levels of Acot1 and Acot3 were also significantly lower in
the SIRT1-deficient hepatocytes. Furthermore, lentivirus-medi-
ated overexpression of SIRT1 in LKO hepatocytes resulted in
rescue of defective PPARa signaling, and further stimulated
the transcriptional activity of PPARa in control hepatocytes
(Figure 2D). Together, these data suggest that SIRT1 positively
regulates PPARa in a cell-autonomous fashion.Cell Metabolism 9, 327–338, April 8, 2009 ª2009 Elsevier Inc. 329
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Hepatic SIRT1 Regulates Fatty Acid OxidationFigure 3. SIRT1 Regulates Ligand-Dependent PPARa Transactivation
(A) Reduction of SIRT1 activity decreases ligand-dependent PPARa transactivation. In the left panel, pSuper (black bars) or pSuper-SIRT1 RNAi (white bars)
HEK293T cells were cotransfected with luciferase reporters and a construct encoding Gal4 DBD-PPARa LBD fusion protein, then treated with DMSO or PPARa
agonists and analyzed for luciferase activity as described in the Experimental Procedures. In the right panel, pSuper (black bars) and pSuper-SIRT1 RNAi (white
bars) HEK293T cells were transfected with 3 3 PPRE-luciferase construct or a control construct lacking the PPRE, together with constructs expressing murine
PPARa and RXRa. Cells were then treated with increasing doses of WY14643 and analyzed for luciferase activity as described in the Experimental Procedures.
(Data represent mean ± SEM, *p < 0.05.)
(B) Loss of SIRT1 in primary hepatocytes reduces ligand-dependent PPARa transactivation. (Data represent mean ± SEM, *p < 0.05.)
(C) Overexpression of SIRT1 stimulates ligand-dependent PPARa transactivation in mouse H2.35 hepatoma cells (Data represent mean ± SEM, *p < 0.05.)We then investigated the connection between SIRT1 and
transactivation of PPARa using luciferase reporter assays.
HEK293T cells stably infected with an empty vector (pSuper)
or a SIRT1 RNAi construct were transfected with a construct
expressing a chimeric transcription factor with the Gal4
DNA-binding domain (DBD) fused to the PPARa ligand-binding
domain (LBD), followed by treatment with DMSO or PPARa
agonists ciprofibrate (100 mM) or WY (15 mM). As expected, treat-
ment with both PPARa agonists resulted in marked induction of
luciferase activity in control HEK293T pSuper cells. In contrast,
transcriptional response to these agonists was significantly
reduced in HEK293T SIRT1 RNAi cells (Figure 3A, left panel).
We then examined transactivation of PPARa using a luciferase
reporter driven by three tandem repeats of a consensus PPAR
response element (33 PPRE). In control HEK293T pSuper cells,
the PPARa agoinst WY stimulated PPRE-driven luciferase in
a dose-dependent manner, while a mutant reporter (PPRE)
failed to respond to WY treatment (Figure 3A, right panel). The330 Cell Metabolism 9, 327–338, April 8, 2009 ª2009 Elsevier Inc.dose-dependent induction of the PPRE-driven reporter was
significantly blunted in HEK293T SIRT1 RNAi cells. Similar
results were obtained in control and SIRT1-deficient primary
hepatocytes (Figure 3B). We further examined the effect of
elevated SIRT1 levels on the transactivation of the PPRE reporter
(Figure 3C, left panel) and a luciferase reporter driven by the
endogenous promoter of FGF21, a known PPARa target (Bad-
man et al., 2007; Inagaki et al., 2007) (Figure 3C, right panel), in
mouse H2.35 hepatoma cells. Overexpression of SIRT1 resulted
in a dose-dependent increase in the luciferase expression from
both reporters. Taken together, these results demonstrate that
SIRT1 directly regulates PPARa transactivation through PPREs.
SIRT1 Interacts with PPARa and Is Required
for the Activation of PGC-1a
To further investigate the role of SIRT1 in regulating PPARa, we
determined whether SIRT1 physically interacts with PPARa. As
shown in Figure 4A, in HEK293T cells, endogenous SIRT1 was
Cell Metabolism
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(A) SIRT1 interacts with PPARa in HEK293T cells. Cell lysates from HEK293T cells transfected with empty vector or HA-PPARa were treated with DMSO or
WY14643, were then immunoprecipitated (IP) with anti-HA antibodies.
(B) SIRT1 interacts with PPARa in the liver. Liver nuclear extracts from mice treated with vehicle or WY were immunoprecipitated with anti-PPARa antibodies.
(C) SIRT1 interacts with PPARa in vitro. GST-SIRT1 fusion protein was incubated with HA-PPARa (left), or GST-PPARa fusion protein was incubated with myc-
SIRT1 (right) in the presence of 15 mM WY. Top panels show immunoblots of HA-PPARa or Myc-SIRT1. Bottom panels show ponceau S staining of GST fusion
proteins.
(D) GST-PPARa interacts with the catalytic core domain of SIRT1. GST-PPARa fusion protein was incubated with indicated Myc-tagged SIRT1 fragments in the
presence of 15 mM WY.
(E) The catalytic core domain of SIRT1 interacts with the both DNA-binding domain (DBD) and ligand-binding domain (LBD) of PPARa. GST-SIRT1 (aa 194–497)
fusion protein was incubated with HA-tagged full-length (F), DBD, or LBD of PPARa.
(F) SIRT1 localizes to the PPRE of PPARa targets. Primary hepatocytes treated with DMSO or WY for 4 hr were subjected to ChIP with IgG control (white bars) or
anti-SIRT1 (black bars) antibodies and analyzed by qPCR with primers flanking PPRE in the promoters of FGF21, Acot1, and Ehhadh. (Data represent mean ±
SEM, *p < 0.05.)
(G) SIRT1 is recruited to the PPRE ofCyp4A10 upon fasting. ChIP assays were performed with chromatin extracts from livers of control mice that were fed, fasted
for 24 hr, or fasted for 24 hr then refed for 24 hr. (Data represent mean ± SEM, n = 4, *p < 0.05.)coimmunoprecipitated by anti-HA antibodies only when HA-
PPARawas expressed, indicating a specific interaction between
these two proteins. To confirm that SIRT1 and PPARa are
present in common protein complexes in vivo, mouse liver
nuclear extracts were precipitated with anti-PPARa antibodies.
As shown in Figure 4B, endogenous SIRT1 was pulled down
specifically by anti-PPARa antibodies but not by IgG. Oral
administration of WY for 2 hr further increased the interaction
between SIRT1 and PPARa, suggesting that SIRT1 preferentially
associates with activated PPARa. Furthermore, the glutathione-
S-transferase (GST)-SIRT1 fusion protein, but not GST control,
pulled down in vitro transcribed and translated HA-PPARa
(Figure 4C, left panel). Reciprocally, the GST-PPARa fusion
protein pulled down Myc-SIRT1 (Figure 4C, right panel), sug-
gesting that SIRT1 directly interacts with PPARa. We further
found that PPARa strongly interacts with the amino acid (aa)
194–497 fragment of SIRT1 encoding the NAD+-dependent de-
acetylase catalytic core domain (Figure 4D). The SIRT1 core
domain, on the other hand, associated with both the DBD andLBD of PPARa (Figure 4E), suggesting that SIRT1 interacts
with PPARa at multiple sites.
The interaction of SIRT1 with PPARa suggested that SIRT1
may associate with PPREs on promoters of PPARa target genes.
To test this possibility, we analyzed the association of SIRT1 with
PPREs using a chromatin immunoprecipitation (ChIP) assay. As
shown in Figure 4F, treatment with WY significantly increased
the association of SIRT1 to the PPREs of a number of PPARa
targets compared to IgG controls, indicating a ligand-dependent
recruitment of SIRT1 to the promoter of PPARa target genes.
Furthermore, SIRT1 was recruited to the PPRE of the Cyp4A10
gene in liver by 24 hr fasting, and dissociated from this PPRE
upon refeeding (Figure 4G), implying that the association of
SIRT1 to PPRE is regulated by the nutritional status.
Previous studies have demonstrated that PGC-1a, an induc-
ible coactivator for a number of nuclear receptors and additional
transcriptional factors, physically interacts with PPARa, thus
stimulating its transcriptional activity (Vega et al., 2000). The
association of PGC-1a with PPARa results in further recruitmentCell Metabolism 9, 327–338, April 8, 2009 ª2009 Elsevier Inc. 331
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Hepatic SIRT1 Regulates Fatty Acid OxidationFigure 5. SIRT1 Is Required to Activate PGC-1a
(A) PGC-1a accumulates on the PPRE of Acot1 in SIRT1 LKO primary hepatocytes. Control and SIRT1 LKO primary hepatocytes treated with DMSO or WY for 4 hr
were subjected to ChIP with IgG control or anti-PGC-1a antibodies and analyzed by qPCR with primers flanking PPRE in the promoter of Acot1. (Data represent
mean ± SEM, *p < 0.05.)
(B) Accumulation of PGC-1a and BAF60a on the PPRE of PPARa targets after fasting in the SIRT1 LKO liver. ChIP assays were performed with chromatin extracts
from livers of control (black bars) and SIRT1 LKO (white bars) mice fasted for 16 hr. (Data represent mean ± SEM, n = 4, *p < 0.05.)
(C) PGC-1a protein levels are induced by fasting and repressed by refeeding in both control and SIRT1 LKO mice. Liver extracts from control and SIRT1 LKO mice
that were fed, fasted for 24 hr, or fasted for 24 hr then refed for 24 hr, were immunoblotted with indicated antibodies.
(D) Accumulation of PGC-1a on the PPRE regardless of feeding status. ChIP assays were performed with chromatin extracts from livers of control and SIRT1 LKO
mice that were fed, fasted for 24 hr, or fasted for 24 hr then refed for 24 hr. (Data represent mean ± SEM, n = 4, *p < 0.05.)
(E) SIRT1 deficiency in hepatocytes increases the acetylation of PGC-1a. FLAG-PGC-1a from control (Con) and SIRT1 LKO (LKO) primary hepatocytes were
treated and immunopurified as described in the Experimental Procedures, and analyzed with anti-acetyl-lysine (acetyl-K) antibodies. (Data represent mean ±
SEM, *p < 0.05.).
(F) Decreased PGC-1a coactivation activity on the expression of PPARa target genes in SIRT1-deficient primary hepatocytes. Primary hepatocytes from control
and SIRT1 LKO mice were infected with adenoviruses expressing GFP or PGC-1a, and treated with DMSO or WY as described in the Experimental Procedures.
(Data represent mean ± SEM, *p < 0.05.)
(G) SIRT1-mediated induction of FGF21 requires PPARa and PGC-1a. Primary hepatocytes from control mice were electroporated with a negative control siRNA
or siRNAs against PPARa or PGC-1a. Cells were then infected with lentiviruses expressing GFP or SIRT1, and treated as described in the Experimental Proce-
dures. (Data represent mean ± SEM, *p < 0.05.)of BAF60a and other SWI/SNF chromatin-remodeling
complexes to activate transcription of PPARa targets (Li et al.,
2008). Since mRNA levels of PGC-1a were consistently lower
in livers of SIRT1 LKO mice after fasting (Figure 1D), we postu-
lated that the observed reduction of PPARa signaling was due
to insufficient recruitment of PGC-1a to target promoters.
However, to our surprise, PPRE-associated PGC-1a levels
were dramatically increased in SIRT1 LKO primary hepatocytes
(Figure 5A), and PPRE-associated PGC-1a as well as BAF60a332 Cell Metabolism 9, 327–338, April 8, 2009 ª2009 Elsevier Inc.levels were also significantly elevated in SIRT1 LKO mouse livers
after fasting (Figure 5B). Further analyses indicated that total
PGC-1a protein was still induced by fasting and repressed by re-
feeding in the SIRT1 LKO liver (Figure 5C), but PPRE-associated
PGC-1a was accumulated regardless of feeding status
(Figure 5D). These results suggest that hepatic SIRT1 is required
for maintenance of the recruitment/dissociation cycle of PGC-1a
in response to the metabolic status. PGC-1a is a direct substrate
of SIRT1, and deacetylation of this coactivator by SIRT1
Cell Metabolism
Hepatic SIRT1 Regulates Fatty Acid Oxidationstimulates its activity (Rodgers et al., 2005). Consistent with this
notion, acetylated PGC-1a levels were significantly increased in
SIRT1 LKO primary hepatocytes after treatment with WY
(Figure 5E), and the coactivation activity of PGC-1a on a number
of PPARa targets was significantly blunted in SIRT1-deficient
primary hepatocytes (Figures 5F and S2B).
To determine whether PPARa or PGC-1a is required for the
SIRT1-mediated induction of PPARa target genes, we electro-
porated siRNA against either PPARa or PGC-1a into primary
hepatocytes (Figure S2C), followed by infection with GFP or
SIRT1 lentiviruses. As shown in Figure 5G, in control hepato-
cytes, overexpression of SIRT1 significantly induced the expres-
sion of FGF21, whereas this induction was abolished in PPARa
RNAi cells, indicating that SIRT1 induces the expression of
PPARa targets through PPARa. The requirement of PPARa
was supported by the luciferase reporter assays in Figure 3
(particularly Figure 3C), which indicate that SIRT1 regulates the
expression of PPARa targets through the PPRE. RNAi of PGC-
1a caused a compensative increase of PPARa levels in hepato-
cytes (Figure S2F), resulting in higher basal levels of FGF21
(Figure 5G; right panel, DMSO). However, overexpression of
SIRT1 failed to further increase expression of FGF21, indicating
that SIRT1 requires PGC-1a to activate PPARa. Interestingly, our
data show that PGC-1a is under the transcriptional control of
PPARa and SIRT1 in primary hepatocytes (Figure S2E).
Hepatic Deletion of SIRT1 Impairs Lipid Homeostasis
upon High-Fat Feeding
Activation of PPARa by fasting promotes lipolysis in white
adipose tissues and stimulates fatty acid oxidation and ketogen-
esis in the liver. The regulation of PPARa by SIRT1 suggests that
loss of function of SIRT1 could impair PPARa-mediated lipid
homeostasis in vivo. Indeed, SIRT1 LKO mice fed a chow diet
accumulated about two folds of triglycerides in the liver after
16 hr fasting (Figure S3A), although their serum free fatty acid
levels remained normal (Figure S3E).
To further examine the pathophysiological effects of blunted
PPARa signaling in vivo, Lox control and SIRT1 LKO mice were
fed ad libitum a western diet providing 40% Kcal fat and 0.21%
cholesterol for 11 weeks, then sacrificed after 16 hr fasting.
Although SIRT1 LKO mice showed no body weight abnormality
on a chow diet (data not shown), they gained significantly more
weight than control mice on the western diet (Figure 6A). Consis-
tent with diet-induced obesity, SIRT1 LKO mice showed greater
lipid accumulation in the liver compared to control mice, as
revealed by H&E staining of liver sections (Figure 6B) and enzy-
matic colorimetric quantification of extracted liver triglycerides,
NEFA, and cholesterol (Figure 6C–6E). Their serum free fatty
acid levels were also significantly increased as compared to
control mice (Figure 6G). Additionally, serum b-hydroxybutyrate,
a marker for fatty acid oxidation and ketogenesis in the liver, was
significantly lower in the SIRT1 LKO mice (Figure 6I).
Increases in hepatic lipids, particularly NEFA, along with
a decrease in serum b-hydroxybutyrate after fasting, indicate
a defect in the fatty acid oxidation pathway. In line with these
observations, levels of PPARa targets known to regulate fatty
acid oxidation were significantly lower in SIRT1 LKO mouse livers
(Figure 6J). A similar reduction in the expression of mitochondrial
oxidative phosphorylation genes (Cytochrome C, Cox4, andCox5b) was observed in these mice. Again, the decreased
expression of the above-mentioned PPARa target genes was
accompanied by a 40% decrease in the expression of PGC-1a
mRNA (Figure 6J). In addition, SIRT1 LKO mice displayed signif-
icantly lower mRNA levels of mitochondrial glycerol-3-phosphate
acyltransferase (mtGPAT), acyl coenzyme A: diacylglycerol acyl-
transferase 1 (DGAT1), and acyl coenzyme A: diacylglycerol acyl-
transferase 2 (DGAT2), genes involved in the esterification of fatty
acids to glycerol for the synthesis of triglycerides, suggesting that
the increase in liver free fatty acids (Figure 6D) in SIRT1 LKO mice
may also be a consequence of impaired fatty acid esterification.
The considerably higher liver cholesterol levels in SIRT1 LKO
mice prompted us to analyze expression of genes involved in
cholesterol synthesis, transport, uptake, efflux, and degradation.
While the major cholesterol uptake genes LDLR and SR-BI were
decreased or unchanged (Figure 6J), there were no observable
differences in levels of cholesterol synthesis (SREBP2,HMGCoA
reductase) or efflux genes (ABCA1, ABCG1, ABCG8) (data not
shown), indicating that the elevated hepatic cholesterol is not
due to increased uptake, synthesis, or decreased efflux. Instead,
Cyp7A1, the rate-limiting enzyme involved in the conversion of
cholesterol to bile acids (Kalaany and Mangelsdorf, 2006), as
well as other enzymes in the bile acid synthesis pathway, were
decreased in SIRT1 LKO mice (Figure 6J), suggesting that the
accumulation of hepatic cholesterol may be the result of dimin-
ished bile synthesis.
Hepatic Deletion of SIRT1 Leads to Hepatic
Inflammation and ER Stress on the High-Fat Diet
It is being increasingly recognized that obesity is associated with
inflammation and cellular stress signaling (reviewed by Wellen
and Hotamisligil, 2005). Excess lipid accumulation in peripheral
tissues promotes macrophage infiltration, thus stimulating local
inflammation and eventually insulin resistance (Kanda et al.,
2006; Weisberg et al., 2003). Excess lipid accumulation in tissues
has also been linked to the development of endoplasmic retic-
ulum (ER) stress, which has also been implicated in inhibition of
the insulin signaling pathway (Ozcan et al., 2004). The accumula-
tion of lipids in the livers of SIRT1 LKO mice led us to examine
whether SIRT1 LKO mice fed a high-fat diet suffer from increased
ER stress and inflammation in the liver.
ER stress provokes an ER transmembrane protein kinase,
pancreatic ER kinase (PERK), to phosphorylate the a subunit of
the translation initiation factor (eIF2a) thus blocking cellular
protein translation (Harding et al., 1999; Shi et al., 1998).
Comparison of levels of phosphorylated eIF2a in liver extracts
of control and SIRT1 LKO mice revealed that SIRT1 LKO mice
had a 2.2-fold increase in p-eIF2a protein compared to Lox
controls (Figure 7A). Hyperactivation of c-Jun N-terminal kinase
(JNK) through phosphorylation is another marker of ER stress
(Urano et al., 2000). Phosphorylation of JNK (p-JNK) and its
downstream target c-Jun (p-c-Jun) were significantly increased
by 2.1-fold and 3.2-fold respectively in SIRT1 LKO mice
compared to control mice (Figure 7A). Together, these findings
indicate that accumulation of lipids in SIRT1 LKO results in
elevated ER stress in the liver.
Infiltration of macrophages into tissues is a hallmark of local
inflammation. Analysis of mRNA from livers of SIRT1 LKO mice
revealed a 70%–80% increase in macrophage markers, includingCell Metabolism 9, 327–338, April 8, 2009 ª2009 Elsevier Inc. 333
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Hepatic SIRT1 Regulates Fatty Acid OxidationFigure 6. Hepatic Loss of SIRT1 Function Impairs Lipid Homeostasis upon High-Fat Diet Feeding
(A) Body weight gain and food intake curves of control and SIRT1 LKO mice (n = 10–11) under western diet. Arrow indicated the beginning of western diet feeding.
(Data represent mean ± SEM, *p < 0.05.)
(B–E) SIRT1 LKO mice accumulate more lipids in the liver after fasting as indicated by (B) Hematoxylin and eosin staining of liver sections from control and SIRT1
LKO mice; and total liver triglycerides (C), free fatty acids (D), and cholesterol (E) levels. (Data represent mean ± SEM, n = 4–5, *p < 0.05.)
(F–I) SIRT1 deficiency in the liver increases serum free fatty acids but reduces serum b-hydroxybutyrate after fasting. Serum triglycerides (F), free fatty acids (G),
cholesterol (H), and b-hydroxybutyrate (I) were analyzed as described. (Data represent mean ± SEM, n = 4–5, *p < 0.05.)
(J) Relative expression of genes encoding key factors in hepatic fatty acid oxidation, oxidative phosphorylation (OXPHOS), fatty acid esterification, bile acid (BA)
metabolism, and cholesterol uptake. (Data represent mean ± SEM, n = 4–5, *p < 0.05.)macrophage inflammation protein (MIP1a) andF4/80+ (Figure 7B).
Notably, several proinflammatory molecules that are dramatically
induced in PPARa-deficient livers (Stienstra et al., 2007), such
as vascular cell adhesion molecule (VCAM-1), serum amyloid
A-1 (SAA-1), and interferon (IFN)-g inducible protein (CXCL10),
were significantly higher in livers of SIRT1 LKO mice compared
to Lox controls (Figure 7B). TNFa and IL-1b, two major proinflam-
matory cytokines induced by fat accumulation, were also signifi-
cantly increased in the liver of SIRT1 LKO mice (Figure 7C). These
observations indicate that SIRT1 LKO mice are prone to develop-
ment of hepatic inflammation. However, livers of high-fat diet fed
SIRT1LKO mice showed very low levels of collagen deposition
(Figure 7D), a hallmark of liver fibrosis, suggesting a full-blown
steatohepatitis has not yet been developed under the current
high-fat diet feeding conditions.
Since bothER stress and inflammation directly contribute to the
development of insulin resistance (Wellen and Hotamisligil, 2005),334 Cell Metabolism 9, 327–338, April 8, 2009 ª2009 Elsevier Inc.our observations imply that SIRT1 LKO mice would show signs of
altered insulin signaling. Indeed, after feeding with a high-fat diet,
Ser473 phosphorylation of Akt, a key molecule in the insulin-
signaling pathway, was 80% lower in livers of SIRT1 LKO mice
(Figure 7F), despite a trend of higher blood insulin levels (Fig-
ure 7E). Interestingly, high insulin levels in these mice were still
able to stimulate the expression of key synthesis/uptake genes,
such asSREBP-1c, fatty acid synthase (FAS), acetyl CoA carbox-
ylase (ACC1, ACC2), and lipoprotein lipase (LPL), on both chow
(Figure S3I) and high-fat diets (Figure 7G), indicating that insulin
signaling is selectively impaired in the SIRT1 LKO mice.
DISCUSSION
Hepatic nuclear receptors play an important role in the regulation
of lipid metabolism, storage, transport, and elimination in
response to nutrient and hormonal cues. Dysfunction of these
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Hepatic SIRT1 Regulates Fatty Acid OxidationFigure 7. Hepatic Deletion of SIRT1 Causes Hepatic Inflammation and ER Stress upon High-Fat Diet Feeding
(A) SIRT1 deficiency in liver increases ER stress. ER stress markers were analyzed by immunoblotting as described.
(B) SIRT1 LKO mice display increased hepatic inflammation. Expression of macrophage markers and proinflammatory genes in the livers of control (black bars)
and SIRT1 LKO mice (white bars) was analyzed by qPCR. (Data represent mean ± SEM, n = 4–5, *p < 0.05.)
(C) SIRT1 LKO mice display increased hepatic levels of proinflammatory cytokines. Liver extracts from control and SIRT1 LKO mice were analyzed for TNFa and
IL-1b by ELISA. (Data represent mean ± SEM, n = 4–5, *p < 0.05.)
(D) Normal deposition of collagen in the SIRT1 LKO livers. The liver sections from control and SIRT1 LKO mice were stained with Sirius red for collagen. Mice in
(A) to (D) were fed a western diet and scarified after 16 hr fasting.
(E) Serum insulin and leptin from control (black bars) and SIRT1 LKO (white bars) mice. (Data represent mean ± SEM, n = 4–5.)
(F) SIRT1 LKO mice display signs of hepatic insulin resistance. (Data represent mean ± SEM, n = 4, *p < 0.05.)
(G) SIRT1 deficiency in the liver increases hepatic lipogenesis. Mice in (E to G) were fed a western diet and scarified after 4 hr fasting. (Data represent mean ± SEM,
n = 4–5, *p < 0.05.)receptors is linked to a number of age-associated metabolic
diseases, including diabetes, obesity, and atherosclerosis
(Chawla et al., 2001). In the present study, we identify PPARa
signaling as a central pathway affected by hepatic deletion of
SIRT1. We observed that blunted PPARa signaling in SIRT1
LKO mice resulted in decreased fatty acid oxidation and keto-
genesis (Figure 2), contributing to the development of hepatic
steatosis, inflammation, and ER stress on a high-fat diet (Figures
6 and 7).
Several lines of evidence suggest a link between SIRT1 and
PPARa. For instance, both SIRT1 and PPARa are activated by
fasting and food restriction (Cohen et al., 2004; Hashimoto
et al., 2000; Kersten et al., 1999; Rodgers et al., 2005). PGC-1a,
a key coactivator for PPARa signaling (Li et al., 2008; Vega
et al., 2000), is a direct substrate of SIRT1 (Rodgers et al.,
2005). Here we show that PPARa signaling is significantly
impaired in SIRT1 LKO mice, while increased SIRT1 levels stim-
ulate PPARa activity (Figure 2), providing a direct link between
SIRT1 and PPARa. Furthermore, our data suggest that SIRT1
regulates PPARa signaling primarily through the activation of
PGC-1a (Figure 5). In SIRT1-deficient hepatocytes, PGC-1a is
still recruited to the PPREs on the promoter of fatty acid oxidation
genes (Figures 5A and 5B). However, it remains in a hyperacety-lated state (Figure 5E) that inhibits its ability to promote transcrip-
tion (Figure 5F). How acetylation affects the activity of PGC-1a is
still not well understood. Since PGC-1a is highly accumulated on
the promoter regions of PPARa target genes in SIRT1-deficient
cells (Figures 5A and 5B), it is possible that SIRT1 is required to
efficiently remove less-activated PGC-1a from the promoters to
allow recruitment of active PGC-1a for additional rounds of tran-
scription. This mechanism has been well described for other
SIRT1-mediated transcriptional activations (Kitamura et al.,
2005; Li et al., 2007; Pagans et al., 2005).
In addition to fatty acid oxidation, PGC-1a also stimulates
hepatic gluconeogenesis in response to fasting (Herzig et al.,
2001; Yoon et al., 2001). The decreased coactivation activity of
PGC-1a in SIRT1 LKO mice suggests that gluconeogenesis
may be impaired. However, we failed to observe notable defects
in the hepatic gluconeogenesis in the SIRT1LKO mice (Figure S5).
Fasting glucose levels in SIRT1 LKO mice were normal under
a chow diet, and were slightly increased under the western diet
or a high-fat diet (Figure S5A). mRNA levels of two rate-limiting
enzymes in the hepatic gluconeogenesis pathway, phosphoenol-
pyruvate carboxykinase (PEPCK) and glucose-6-phosphatase
(G6Pase), were also normal (Figure S5B). These observations
are not surprising, given the fact that SIRT1 also deacetylatesCell Metabolism 9, 327–338, April 8, 2009 ª2009 Elsevier Inc. 335
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2004), two additional key factors involved in promoting gluconeo-
genesis in the early and late fasting phases, respectively.
Therefore, the net effect of loss of SIRT1 on gluconeogenesis is
determined by the complex compensatory patterns of multiple
factors.
An intriguing observation in the present study is that the effect
of SIRT1 on fatty acid metabolism is coupled with altered choles-
terol metabolism. Not only do SIRT1 LKO mice accumulate
massive amounts of cholesterol when fed a western diet (Fig-
ure 5E), they also accumulate significantly higher hepatic choles-
terol when fed a high-fat diet without cholesterol (Figure S4).
These observations suggest increased de novo synthesis is
the major source of hepatic cholesterol. However, the expres-
sion levels of two key mediators of cholesterol synthesis,
SREBP2 and HMGCoA reductase, were normal in SIRT1 LKO
mice on the western diet. Hence, the increased synthesis may
be due to an increase in the availability of substrates through
accumulated hepatic free fatty acids (Figure 6D).
The metabolic phenotypes observed in SIRT1 LKO mice are in
line with several previous reports. For example, activation of
SIRT1 by the polyphenol resveratrol and several synthetic phar-
macologic activators has been shown to protect against high-fat
induced obesity and metabolic derangements (Baur et al., 2006;
Lagouge et al., 2006; Milne et al., 2007). Manipulation of SIRT1
levels in the liver has been reported to affect the expression of
a number of genes involved in glucose and lipid metabolism
(Rodgers and Puigserver, 2007). Additionally, recent studies
demonstrated that modest overexpression of SIRT1 resulted in
a protective effect against high-fat induced hepatic steatosis
and glucose intolerance (Banks et al., 2008; Pfluger et al.,
2008). Our observations from SIRT1 LKO mice suggest that
hepatic SIRT1 mediates a fine balance between energy influx
and energy expenditure in the liver. However, it is important to
note that although insulin signaling is impaired in the livers of
SIRT1 LKO mice (Figure 7F), they show normal insulin sensitivity
and fuel metabolism in white adipose tissue and muscle, and
thus do not develop systemic glucose intolerance (Figure S5C).
Several of the observed metabolic alterations in the SIRT1 LKO
mice are in contrast from those observed in some SIRT1 knockout
animal studies (data not shown) (Chen et al., 2008). For example,
SIRT1 LKO mice gain significantly more weight than wild-type
mice and develop hepatic steatosis when fed with high-fat diets
(Figures 6A and S4). However, whole-body SIRT1 knockout
mice are protected from high-fat diet-induced obesity and fatty
liver (X.L. and L. Guarente, unpublished data). A distinguishing
difference between these two knockout models is their overall
growth condition. SIRT1 LKO mice have no obvious phenotypic
abnormalities under normal dietary conditions, whereas whole
body SIRT1 knockouts suffer severe growth retardation, which
can likely be attributed to a number of developmental defects
(Cheng et al., 2003; McBurney et al., 2003). In addition, defective
SIRT1 function in other tissues is likely to systemically affect
energy metabolism in the whole body SIRT1 knockout mice,
making it difficult to dissect hepatic specific function of SIRT1.
In summary, we have shown that hepatic SIRT1 plays an
important role in the regulation of lipid metabolism in response
to nutrient and hormonal signals. While it has been reported
that SIRT1 systemically regulates energy homeostasis in many336 Cell Metabolism 9, 327–338, April 8, 2009 ª2009 Elsevier Inc.metabolic tissues by modulating a variety of signaling pathways,
we show that in the liver, a major target of this sirtuin is the
PPARa/PGC-1a signaling pathway and fatty acid oxidation.
Our findings provide a direct link between SIRT1 and hepatic
fatty acid metabolism, and suggest that therapeutic strategies
designed to modulate SIRT1 activity may be beneficial for the
treatment of hepatic diseases as well as obesity-associated
metabolic syndrome.
EXPERIMENTAL PROCEDURES
Animal Experiments
SIRT1 allele with floxed exon 4 (Cheng et al., 2003) was backcrossed five times
into the C57BL/6 background. It was then bred with mice expressing the Cre
recombinase driven by the albumin promoter (Jackson Laboratory) to generate
liver-specific SIRT1 knockout mice (SIRT1 LKO) in over 98% C57BL/6 back-
ground. SIRT1 LKO mice and their age-matched littermate Lox controls
(Cre/, SIRT1flox/flox) older than 6 weeks of age were fed ad libitum either
a standard laboratory chow diet or a high-fat western diet (D12079B, Research
Diets) for 11 weeks. All animal experiments were conducted in accordance with
guidelines of NIEHS/NIH Animal Care and Use Committee.
Histological and Biochemical Analysis
Paraffin-embedded liver sections were stained with hematoxylin and eosin for
morphology or sirius red for collagen. Serum NEFA, cholesterol, and triglycer-
ides were measured using commercially available kits (WAKO and Sigma).
Serum insulin and leptin levels were measured by ELISA (Meso Scale
Discovery). Liver lipids were extracted as described (Danno et al., 1992),
and liver triglycerides, NEFA, and cholesterol were quantified by commercially
available kits (Sigma and Wako).
Cell Culture
HEK293T cells stably infected with pSuper or pSuper-SIRT1 RNAi have been
described (Li et al., 2007). Mouse primary hepatocytes were isolated from
control or SIRT1 LKO mice using collagenase perfusion, seeded on collagen-
coated plates in seeding medium (high glucose DMEM, 10% FBS, 100 nM
insulin, 1 mM dexamethasone), and maintained in maintenance medium (low
glucose DMEM, 0.1% bovine serum albumin). To induce the expression of fatty
acid oxidation genes, primary hepatocytes were preincubated with 125 mM
palmitic acid/BSA for overnight in the presence or absence of 30 mM
WY14643 in low glucose medium, followed by incubation with 125 mM palmitic
acid/BSA and 1 mM Carnitine in glucose free DMEM medium for 4 hr.
Fatty Acid b-Oxidation
Primary hepatocytes isolated from SIRT1 LKO mice or Lox controls were
preincubated with 500 mM palmitic acid/BSA in maintenance medium for
24 hr in the presence or absence of 30 mM WY14643 followed by incubation
with 125 mM 3H palmitic acid (Sigma)/BSA and 1 mM Carnitine in PBS for
2 hr. 3H20 was measured as described previously.
Luciferase Assay
For transactivation experiments, cells were transfected with indicated fire-fly
luciferase reporter and control pRL-TK (Renilla Luciferase, Promega). Cells
were incubated with or without PPARa agonists as indicated for 24 hr and
luciferase activity was measured using the Dual-Luciferase Reporter Assay
System (Promega). The final firefly luciferase activity was normalized to the
coexpressed renilla luciferase activity.
Western Blot Analysis, Coimmunoprecipitation, and ChIP Analysis
Liver whole-cell homogenates were prepared with NP40 buffer (50 mM Tris-
HCL, pH 8.0, 150 mM NaCl, 0.5% NP40) containing Complete protease and
phosphatase inhibitors (Roche), and then immunoblotted using antibodies
against p-JNK, JNK, p-Elf2a, Elf2a, p-cJun, p-Akt, and Akt (Cell Signaling
Technology, Inc.).
For endogenous immunoprecipitation between SIRT1 and PPARa, control
mice were oral gavaged with vehicle or 30 mg/kg WY for 2 hr, liver nuclear
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Hepatic SIRT1 Regulates Fatty Acid Oxidationextracts were then immunoprecipitated with anti- PPARa antibodies (H-98;
Santa Cruz Biotechnology, Inc.).
ChIP analysis was performed as described by Upstate Biotechnology with
antibodies against SIRT1, PGC-1a (Santa Cruz Biotech and Chemicon),
PPARa (Affinity BioReagents), BAF60a (BD Biosciences), or normal rabbit
IgG. DNA fragments were subjected to qPCR using primers flanking PPRE
on various PPARa targets.
Protein Acetylation Analysis
Primary hepatocytes from Lox control (control) and SIRT1 LKO (LKO) mice
were infected with lentiviruses expressing FLAG-PGC-1a. Seventy-two hours
after infection, hepatocytes were treated with WY14643 for three hours, and
incubated with 25 mM MG132, 1 mM TSA, and WY for an additional hour.
FLAG-PGC-1a was immunopurified with anti-FLAG m2 beads (Sigma) and
analyzed with anti-acetyl-lysine polyclonal antibodies (Cell Signaling Tech-
nology, Inc.).
Statistical Analysis
Values are expressed as mean ± standard error of mean (SEM). Significant
differences between means was analyzed by two-tailed, unpaired Student’s
t test, and differences were considered significant at p < 0.05.
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